We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.105 | 0.34% | 30.585 | 30.57 | 30.60 | 30.6085 | 30.45 | 30.48 | 1,381,392 | 19:02:30 |
By Chris Wack
Atea Pharmaceuticals Inc. reported positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate Covid-19.
Roche Holding AG and Atea are jointly developing AT-527, an oral direct-acting antiviral agent derived from Atea's purine nucleotide prodrug platform.
The biopharmaceutical company said the interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with Covid-19, of which data from 62 patients were evaluable for virology analysis.
Interim virology results indicated that AT-527 rapidly reduced viral load levels. At Day 2, patients receiving AT-527 experienced an 80% greater mean reduction from baseline viral load as compared with placebo. A sustained difference in viral load reduction was maintained through Day 8, the company said.
By Day 14, the last viral sampling study day, 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus. Nasopharyngeal swabs were measured in a reverse transcription polymerase chain reaction test for the quantitative detection of nucleic acid from SARS-CoV-2, the company said.
Consistent with previous studies, AT-527 was generally safe and well tolerated, the company said.
In this study, there were no drug-related serious adverse events. Nonserious adverse events were equally distributed across treatment arms. Most were mild-to-moderate in severity and assessed as not related to the study drug. No safety concerns or newly determined risks were identified, the company said.
Atea shares were up 5% to $25.43 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 30, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions